Home » AGEB Journal » Issues » Volume 67" » Fasc.1 - Guidelines » Article details

BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma

Journal Volume 67 - 2004
Issue Fasc.1 - Guidelines
Author(s) Hans Van Vlierberghe, Ivan Borbath, Jean Delwaide, Jean Henrion, Peter Michielsen, Chris Verslype
Full article
Full Article
(1) Dpt of Gastroenterology, Ghent University Hospital, Gent, Belgium ; (2) Dpt of Gastroenterology, Hôpital St Luc, UCL, Brussels, Belgium ; (3) Dpt of Gastroenterology, CHU, Sart Tilman, Liège, Belgium ; (4) Dpt of Gastroenterology, Jolimont Hospital, Haine St Paul, Belgium ; (5) Dpt of Gastroenterology, University Hospital, Antwerp, Belgium ; (6) Dpt of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium.

Hepatocellular carcinoma (HCC) is a primary tumour of the liver. Its behaviour is rather peculiar with progno- sis made out not only by the tumoural disease but also by the severity of the underlying liver disease. Worldwide it is a major problem. In the West, however, the prevalence is lower than in developing countries. However due to a rise in HCV induced liver cirrhosis, HCC becomes more prevalent in Belgium. In the HepCar registry (a Belgian registry where on a voluntary basis, patients with HCC are reported), 70 patients (51 male / 19 female) were reported between January 2003 and September 2003. Median age was 62 years ± 12. Underlying liver disease was HCV in 29 patients, HBV in 14 patients, alcoholic liver disease in 16 patients and miscellaneous in 12 patients. Diagnosis was made by surveillance in 27 patients. There was a clear tenden- cy for incidental diagnosis in patients with alcoholic liver disease.

© Acta Gastro-Enterologica Belgica.